Article Impact Level: HIGH Data Quality: STRONG Summary of Circulation https://doi.org/10.1161/CIRCULATIONAHA.125.074493 Dr. Weihong Tang et al.
Points
- Investigators utilized high-throughput proteomics on blood samples from twenty thousand adults to identify twenty-three specific proteins that significantly correlate with the long-term risk of developing dangerous venous thromboembolism.
- The findings revealed fifteen novel proteins previously unknown to science that link blood clot formation to biological processes like immune system function and the regulation of the extracellular matrix.
- Genetic analyses indicated that several identified proteins may exert a direct causal influence on clot development rather than simply serving as passive indicators of an existing clinical risk state.
- The study tracked participants for up to twenty-nine years and successfully validated the initial findings in a separate independent cohort consisting of nearly forty thousand additional adult participants.
- These results provide new modifiable targets for clinical prevention and treatment strategies that could eventually improve patient outcomes through more precise cardiovascular risk stratification and targeted therapy.
Summary
This study evaluated the use of large-scale high-throughput aptamer-based proteomics to identify novel circulating biomarkers and biological pathways for incident venous thromboembolism. Given that the etiology of this leading cardiovascular disease remains incompletely understood, the research sought to analyze data from more than 20,000 adults across four long-term prospective studies. Participants were tracked for 10 to 29 years, allowing investigators to measure thousands of plasma proteins at baseline and determine their relationship to future clot formation before validating the results in an independent cohort of nearly 40,000 participants.
The analysis identified 23 plasma proteins significantly linked to venous thromboembolism risk, including 15 novel proteins previously unassociated with the condition. These biomarkers reflect diverse biological processes beyond established pathophysiology, including extracellular matrix regulation, immune-vascular endothelium interactions, and vascular senescence. Genetic analyses further suggested that several of these proteins may play a direct causal role in thrombosis rather than merely serving as risk signals. The study provides a foundational roadmap for utilizing these markers to improve risk stratification and identify new modifiable targets for therapeutic intervention.
The findings suggest that the drivers of clot risk extend to systemic inflammatory and tissue repair pathways. By identifying these specific proteomic signals, clinicians may better predict which individuals are at a higher risk for life-threatening events. The scale of the prospective design and the robust validation in independent populations strengthen the conclusions regarding protein-clot associations. Future research will focus on confirming these pathways in more diverse demographics and investigating the functional mechanisms through which these proteins contribute to vascular senescence and the eventual development of venous thromboembolism.
Link to the article: https://advanced.onlinelibrary.wiley.com/doi/10.1002/aelm.202600004
References
Tang, W., Li, A., Austin, T. R., Brækkan, S. K., Nøst, T. H., Li, X., Deo, R., Dubin, R., Ganz, P., Guan, W., Cao, R., Hansen, J.-B., Hveem, K., Hoogeveen, R. C., Jonasson, C., Rotter, J. I., Matsushita, K., Liu, G., Pankow, J. S., … Folsom, A. R. (2026). Novel plasma proteomic markers and risk of venous thromboembolism. Circulation, 153(11), 810–825. https://doi.org/10.1161/CIRCULATIONAHA.125.074493
